Saltar al contenido principal
Elsevier

Annual Reports in Medicinal Chemistry

New Approaches in Conjugate Drug Design: Part 1

  • 1 Edición, Volumen 67 - 1 de noviembre de 2026
  • Última edición
  • Editor: Katherine Seley-Radtke
  • Idioma: Inglés

New Approaches in Conjugate Drug Design: Part 1, published as Volume 67 of the serial Annual Reports in Medicinal Chemistry, provides a comprehensive overview of current strategies… Leer más

Descripción

New Approaches in Conjugate Drug Design: Part 1, published as Volume 67 of the serial Annual Reports in Medicinal Chemistry, provides a comprehensive overview of current strategies in the design and application of drug conjugates. Chapters cover small molecule drug conjugates, antibody-to-small molecule carrier approaches, antibiotic-derived and terpene-derived antimicrobial conjugates, aptamer-RNA conjugates, and phenolic and metal natural product conjugates. Applications span anticancer, antiviral, antifungal, and theranostic therapies, including photoactivatable therapy and emerging approaches in quantum oncology. The volume serves as a reference on design principles, therapeutic applications, and clinical progress in conjugate-based drug discovery.

Puntos claves

  • Surveys design principles, therapeutic applications, and clinical progress of small molecule drug conjugates
  • Covers diverse conjugate classes, including antibiotic-derived, terpene-derived, aptamer-RNA, phenolic, and metal natural product conjugates
  • Addresses applications across anticancer, antiviral, antifungal, and antimicrobial drug discovery
  • Includes emerging approaches such as theranostic conjugates, photoactivatable therapy, and quantum oncology
  • Features contributions from an international group of expert authors

De interès para

Medicinal chemists and drug discovery scientists working on targeted therapeutics; researchers in oncology drug development and anti-infective (antibacterial, antiviral, antifungal) drug design; chemical biologists and pharmaceutical scientists focused on prodrugs, drug delivery, and conjugation chemistry; graduate students and postdoctoral researchers in medicinal chemistry.

Índice

  1. From Antibody to Small Molecule Carriers: Targeted Conjugation Under Prodrug Constraints
  2. Small Molecule Drug Conjugates: Design Principles, Therapeutic Applications, and Clinical Progress
  3. Antibiotic-Derived Conjugates
  4. Small-Molecule Drug Conjugates in Anticancer Drug Discovery: Design Strategies, Molecular Hybridization, and Therapeutic Applications
  5. Aptamer-RNA Conjugates for Precision Medicine: Design Principles, Therapeutic Applications, and Future Perspectives
  6. Architecting Small Molecule–Drug Conjugates for the Future of Theranostic and Combinatorial Oncology
  7. Small Molecule Drug Conjugates: Current Progress and Future Directions Toward Precision Therapeutics (2026–2035)
  8. Small-Molecule Drug Conjugates as a Novel Strategy Against Emerging Respiratory Viruses, Such as Influenza Viruses and SARS-CoV-2
  9. Small Molecule Drug Conjugates
  10. Phenolic Small Molecules and Their Conjugates for Antiviral, Antioxidant, and Immunomodulatory Drug Development
  11. Beyond Ergosterol and the Cell Wall: New Directions in Antifungal Drug Discovery
  12. Quantum Oncology
  13. Metal Natural Product Complexes as Emerging Anticancer Chemoimmunotherapeutic Agents
  14. Terpene-Derived Antimicrobial Hybrids and Conjugates: Design, Synthesis, and Structure-Activity Relationships
  15. Medicinal Chemistry of IR700-Silicon Phthalocyanine Based Photoactivatable Therapy

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 67
  • Publicado: 1 de noviembre de 2026
  • Idioma: Inglés

Sobre el editor

KS

Katherine Seley-Radtke

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as the Program Director for UMBC’s Chemistry-Biology Interface graduate training program funded by NIH since 2007. This program promotes hands on cross disciplinary research for almost 50 PhD students from four departments at UMBC and UMB. She is currently the Immediate Past President and Secretary-Elect for the International Society of Nucleosides, Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy, Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Afiliaciones y experiencia
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA